{"entity":{"id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","aka":[],"tldr":"A phase 1/2 trial of DS3790a in non-Hodgkin lymphoma, run by Daiichi Sankyo, now recruiting.","summary":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies is a phase 1/2 interventional study registered as NCT07220616 by Daiichi Sankyo, with 420 participants planned, started 2026-01-16 and due to reach its primary completion in 2030-11-30. Interventions recorded: DS3790a and Combination drug.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07220616","url":"https://clinicaltrials.gov/study/NCT07220616"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07220616","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies","sponsor":"Daiichi Sankyo","enrolled":420,"outcomes":[]},"route":"/trials/nct07220616/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}